Ipsen Future Growth
Future criteria checks 2/6
Ipsen is forecast to grow earnings and revenue by 7% and 6% per annum respectively. EPS is expected to grow by 6.8% per annum. Return on equity is forecast to be 14.6% in 3 years.
Key information
7.0%
Earnings growth rate
6.8%
EPS growth rate
Pharmaceuticals earnings growth | 16.1% |
Revenue growth rate | 6.0% |
Future return on equity | 14.6% |
Analyst coverage | Good |
Last updated | 04 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,949 | 782 | 846 | 1,109 | 11 |
12/31/2025 | 3,692 | 703 | 790 | 1,016 | 12 |
12/31/2024 | 3,468 | 592 | 578 | 845 | 13 |
6/30/2024 | 3,435 | 664 | 425 | 903 | N/A |
3/31/2024 | 3,371 | 641 | 554 | 884 | N/A |
12/31/2023 | 3,306 | 617 | 683 | 866 | N/A |
6/30/2023 | 3,282 | 406 | 764 | 972 | N/A |
3/31/2023 | 3,219 | 500 | 741 | 971 | N/A |
12/31/2022 | 3,156 | 593 | 719 | 971 | N/A |
9/30/2022 | 3,053 | 656 | 615 | 972 | N/A |
6/30/2022 | 2,950 | 719 | 512 | 973 | N/A |
3/31/2022 | 2,849 | 675 | 494 | 933 | N/A |
12/31/2021 | 2,749 | 631 | 475 | 893 | N/A |
9/30/2021 | 2,712 | 626 | 570 | 860 | N/A |
6/30/2021 | 2,676 | 622 | 665 | 827 | N/A |
3/31/2021 | 2,681 | 585 | 649 | 799 | N/A |
12/31/2020 | 2,686 | 548 | 632 | 771 | N/A |
9/30/2020 | 2,697 | 249 | 564 | 750 | N/A |
6/30/2020 | 2,707 | -50 | 496 | 729 | N/A |
3/31/2020 | 2,700 | -53 | 421 | 678 | N/A |
12/31/2019 | 2,693 | -55 | 347 | 628 | N/A |
9/30/2019 | 2,605 | 176 | 310 | 591 | N/A |
6/30/2019 | 2,516 | 406 | 272 | 555 | N/A |
3/31/2019 | 2,432 | 397 | 279 | 563 | N/A |
12/31/2018 | 2,348 | 388 | 285 | 571 | N/A |
9/30/2018 | 2,258 | 365 | N/A | N/A | N/A |
6/30/2018 | 2,167 | 343 | 280 | 502 | N/A |
3/31/2018 | 2,090 | 307 | N/A | 463 | N/A |
12/31/2017 | 2,012 | 270 | N/A | 423 | N/A |
9/30/2017 | 1,923 | 243 | N/A | N/A | N/A |
6/30/2017 | 1,834 | 217 | N/A | 316 | N/A |
3/31/2017 | 1,753 | 221 | N/A | 317 | N/A |
12/31/2016 | 1,671 | 226 | N/A | 318 | N/A |
9/30/2016 | 1,623 | 229 | N/A | N/A | N/A |
6/30/2016 | 1,575 | 233 | N/A | 318 | N/A |
3/31/2016 | 1,548 | 211 | N/A | 271 | N/A |
12/31/2015 | 1,520 | 189 | N/A | 224 | N/A |
9/30/2015 | 1,468 | 165 | N/A | 225 | N/A |
6/30/2015 | 1,416 | 140 | N/A | 227 | N/A |
3/31/2015 | 1,374 | 147 | N/A | 237 | N/A |
12/31/2014 | 1,332 | 154 | N/A | 246 | N/A |
9/30/2014 | 1,310 | 155 | N/A | 217 | N/A |
6/30/2014 | 1,287 | 156 | N/A | 188 | N/A |
3/31/2014 | 1,284 | 149 | N/A | 188 | N/A |
12/31/2013 | 1,282 | 142 | N/A | 188 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0MH6's forecast earnings growth (7% per year) is above the savings rate (1.9%).
Earnings vs Market: 0MH6's earnings (7% per year) are forecast to grow slower than the UK market (14.2% per year).
High Growth Earnings: 0MH6's earnings are forecast to grow, but not significantly.
Revenue vs Market: 0MH6's revenue (6% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0MH6's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0MH6's Return on Equity is forecast to be low in 3 years time (14.6%).